Hansoh Pharmaceutical Group Company Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 3692.HK | 1276.HK | 000999.SZ | 000623.SZ | 600664.SS | 000661.SZ | |
|---|---|---|---|---|---|---|
| Market cap | 213.29B | 350.78B | 43.15B | 20.71B | 14.61B | 30.39B |
| P/E (TTM) | 28.6 | 34.8 | 13.4 | 6.8 | 23.2 | — |
| Forward P/E | 26.2 | 30.7 | 11.7 | 7.9 | 19.3 | 6.7 |
| Price/book | 4.8 | 4.4 | 1.9 | 0.6 | 2.3 | 1.3 |
| Dividend yield | 1.42% | 0.44% | 3.92% | 2.88% | — | 0.22% |
| 1-year change | −5.33% | −28.56% | −11.05% | −16.84% | +55.14% | −30.53% |
| Today | +3.11% | +2.32% | +1.01% | −0.35% | +1.05% | +1.78% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All 3692.HK news ›GSK PLC And Hansoh Pharmaceutical Group Co., Ltd. Announce Positive Phase III Results From ARTEMIS-011 Study Evaluating Risvutatug Rezetecan In China
Published on 10/26/2026 at 11:30 am EDT In ARTEMIS-011, Ris-Rez reduced the risk of disease progression or death by 67% compared with chemotherapy, after a median follow-up of 7.1 months (HR, 0.33; 95% CI, 0.20-0.55; p In the trial, safety…
Can Hansoh Pharmaceutical Monetize Its Expanding Drug Portfolio?
Hansoh Pharmaceutical Group Company Limited's growth from new drug development is translating into stronger earnings, though future returns depend on continued pipeline success. Published on 06/30/2026 at 05:37 am EDT China's…
Hansoh Pharmaceutical Signs ADC Collaboration With Roche
Hansoh Pharmaceutical Group agreed to collaborate with Roche on antibody-drug conjugate programs. The agreement covers two preclinical Hansoh programs and additional programs using Hansoh's ADC... Hansoh Pharmaceutical Group Company…
Rx Rundown: Merck KGaA, GSK, Hansoh Pharmaceutical and more
Check out this week’s medical marketing news, dealmaking and industry chatter. Merck KGaA said it would acquire Silence Therapeutics in an all-cash deal valued at approximately $1.3 billion. Hansoh Pharmaceutical subsidiaries entered into…
Hansoh Pharmaceutical Group Company Limited: Total Return chart (Dividends reinvested) - Hong Kong S.E. stock market
See the history of Hansoh Pharmaceutical Group Company Limited, with dividends reinvested. (Total Return chart) 3692 Stock market Total Return chart Hansoh Pharmaceutical Group Company Limited Past dividends on Hansoh Pharmaceutical Group…
CMB International Capital Adjusts Hansoh Pharmaceutical Group's Price Target to HK$50.54
CMB International Capital Securities on Wednesday adjusted its price target on Hansoh Pharmaceutical Group to HK$50.54 from HK$49.12 and kept its rating at buy. ... Hansoh Pharmaceutical Group Company Limited CMB International Capital…
Hansoh Pharmaceutical Group Company Limited Enters into Strategic Collaboration and License Agreement with F. Hoffmann-La Roche Ltd
Published on 10/19/2026 at 06:08 am EDT The Collaboration Agreement is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in the United…
Hansoh Pharmaceutical Group Company Limited Stock (3692) - Quote Hong Kong S.E.
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com8
- mmm-online.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.